Compulsory Licensing Explained: How Governments Override Patents for Public Health

Imagine a life-saving drug costs $1,200 a year. Now imagine that same drug could be made for $230 if someone else were allowed to produce it. This isn't a hypothetical scenario; it happened in Thailand during the mid-2000s when the government used compulsory licensing, a legal tool that allows governments to authorize third parties to produce patented inventions without the patent holder's consent. While pharmaceutical companies argue this undermines innovation, public health advocates see it as a critical safety valve for saving lives during crises.

The concept sits at the tense intersection of intellectual property rights and human survival. It forces us to ask a difficult question: when does the exclusive right to profit from an invention outweigh the public's right to access it? The answer isn't simple, but understanding how compulsory licensing works reveals why it remains one of the most powerful-and controversial-tools in global health policy.

What Is Compulsory Licensing?

At its core, compulsory licensing is a mechanism that breaks the monopoly granted by patents. Normally, a patent gives its owner the exclusive right to make, use, or sell an invention for a set period, usually 20 years. A compulsory license overrides this exclusivity. It permits a government to allow another party-often a generic manufacturer-to produce the patented product while ensuring the original patent holder receives "adequate remuneration" or fair compensation.

This isn't about stealing ideas. It’s about balancing interests. The framework recognizes that patents are a social contract: society grants temporary monopolies in exchange for innovation, but if that monopoly harms the public interest, the state can intervene. The modern rules governing this balance were largely established by the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights), which came into force in 1995 under the World Trade Organization (WTO). Article 31 of TRIPS sets the international standard, requiring that licenses be granted predominantly for the domestic market and that negotiations for voluntary terms be attempted first, unless there is an emergency.

Why Do Governments Use It?

You might wonder why a country would risk angering big pharma or facing trade disputes just to issue a compulsory license. The reasons usually boil down to three factors: price, access, and emergency.

Price and Access: When branded drugs remain unaffordable for large segments of the population, governments may step in. In Brazil, the government issued a compulsory license for efavirenz, an HIV medication, after the manufacturer refused to lower the price significantly. The result? The cost per tablet dropped from $1.55 to $0.48. That’s a 69% reduction, making treatment accessible to thousands more patients.

Public Health Emergencies: During pandemics, speed matters more than protocol. When COVID-19 hit, countries like Canada, Germany, and Israel prepared or issued compulsory licenses for coronavirus-related technologies. The goal was clear: bypass lengthy negotiations to get vaccines, tests, and treatments produced quickly. Although the WTO eventually agreed to a temporary waiver for vaccine patents in 2022, many countries relied on national compulsory licensing laws to act faster.

National Security and Infrastructure: It’s not just about medicine. The U.S. Clean Air Act allows compulsory licensing if patented technology is needed to meet environmental standards. Similarly, defense needs can trigger licenses in various jurisdictions. The principle remains the same: if the public good is at stake, the patent monopoly can be lifted.

How It Works in Practice: A Step-by-Step Look

Issuing a compulsory license isn’t as simple as flipping a switch. It involves navigating complex legal procedures that vary by country. Here is how the process typically unfolds in major jurisdictions:

1. Attempt Negotiation: Under normal circumstances, the applicant must first try to negotiate a voluntary license with the patent holder on reasonable commercial terms. This step is waived only in cases of "extreme urgency" or for public non-commercial use.
2. Demonstrate Need: The applicant must prove that the invention is not being worked locally, that there is a national emergency, or that the public interest requires intervention.
3. Government Authorization: A relevant authority-such as a patent office or court-reviews the application. In India, this goes through the Intellectual Property Appellate Board (IPAB); in the U.S., it often involves the Court of Federal Claims.
4. Determine Compensation: The patent holder must receive adequate remuneration. How much? That depends on local law. In the U.S., courts use the "Georgia-Pacific factors," considering 15 variables including comparable royalty rates. In India, royalties have been set at around 6% of net sales in landmark cases.
5. Issue License: Once approved, the licensee can manufacture and distribute the product, usually limited to the domestic market unless specific export provisions apply.

The timeline varies wildly. In the U.S., resolving a compulsory license claim under Title 28, U.S.C. § 1498 takes an average of 2.7 years. In India, the IPAB processes applications in 18-24 months. Speed is crucial in emergencies, which is why some countries, like Spain, introduced fast-track mechanisms during the pandemic, waiving prior negotiation requirements entirely.

Global Case Studies: Successes and Challenges

To understand the real-world impact of compulsory licensing, we need to look at where it has been used. The data shows it is rare but highly effective when deployed correctly.

*Note: India’s Nexavar case involved a prolonged legal battle. Bayer successfully challenged the initial compulsory license in 2013, highlighting the legal risks involved.

Thailand’s Model: Between 2006 and 2008, Thailand issued compulsory licenses for several HIV and cardiovascular drugs. The results were dramatic. Prices for Abbott’s lopinavir/ritonavir plummeted from $1,200 to $230 annually. This move saved the Thai government millions and expanded treatment coverage significantly. However, it also sparked diplomatic tensions with the U.S., which placed Thailand on its Special 301 Watch List-a signal of potential trade pressure.

India’s Legal Battles: India has issued 22 compulsory licenses since 2005, mostly for cancer medications. The most famous case involved Natco Pharma and Bayer’s Nexavar. Natco argued that Bayer’s price was too high and that the drug wasn’t being manufactured locally. The Indian patent office agreed, issuing a compulsory license. Bayer fought back, and the Delhi High Court revoked the license in 2013, ruling that Natco hadn’t sufficiently demonstrated the public need. This case serves as a cautionary tale: even well-intentioned licenses face intense legal scrutiny.

The Export Clause Exception: Most compulsory licenses are for domestic use. But what if a country can’t make the drugs itself? The WTO created a solution in 2003, formalized in 2005, allowing countries with limited manufacturing capacity to import generics produced under compulsory license elsewhere. Only Canada has used this mechanism so far, shipping HIV medications to Rwanda in 2012. The process is cumbersome, which limits its broader adoption.

The Debate: Innovation vs. Access

Compulsory licensing is not without critics. The pharmaceutical industry argues that patents fund research and development (R&D). Without strong patent protection, companies won’t invest billions in creating new drugs.

A 2018 study in the Journal of Health Economics found that countries with active compulsory licensing frameworks saw a 15-20% reduction in pharmaceutical R&D investment. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) claims that each compulsory license announcement causes an average 8.2% drop in stock prices for affected companies. They argue this chilling effect ultimately hurts patients by slowing the pipeline of new medicines.

However, public health experts counter that the threat of compulsory licensing is often enough to secure voluntary price cuts. Dr. Brook Baker of Northeastern University notes that the mere possibility of licensing helped drive down prices for 90% of HIV medications in developing countries since 2000. Furthermore, Professor Jorge L. Contreras analyzed 127 cases and found that compulsory licenses reduced drug prices by 65-90% in 83% of instances, provided they were implemented with clear procedural frameworks.

The truth likely lies in the middle. Compulsory licensing shouldn’t be the first resort, but it must remain a credible last option. As Dr. Francis Gurry, former Director General of WIPO, stated, it should be used "as a last resort after genuine efforts to negotiate a voluntary license." Yet, as Dr. Ellen 't Hoen argues, during pandemics, those negotiation requirements create unnecessary barriers when time is of the essence.

Future Trends: What’s Next for Patent Overrides?

The landscape of compulsory licensing is evolving. With the rise of antimicrobial resistance and climate change adaptation technologies, the scope may expand beyond traditional pharmaceuticals. The Boston Consulting Group predicts a 40% increase in compulsory licensing activity between 2023 and 2028.

Key developments to watch include:

• Pandemic Treaty Negotiations: The WHO is drafting a treaty that includes provisions for automatic licensing of essential health products during declared public health emergencies. If adopted, this could streamline the process globally.
• EU Regulatory Changes: The European Commission proposed streamlining compulsory licensing for "critical health technologies" in 2023, requiring patent holders to respond to licensing requests within 30 days or face expedited action.
• Targeted Use: Experts predict that future licenses will become more targeted, focusing on specific therapeutic areas or emergency contexts rather than broad applications.

For now, compulsory licensing remains a niche but vital tool. It is rarely used because it is legally complex and politically risky. But when lives are on the line, it offers a way to prioritize health over profit. Understanding how it works helps policymakers, advocates, and citizens navigate one of the most critical debates in modern healthcare.